Alumis (ALMS) Capital Expenditures (2023 - 2025)
Alumis (ALMS) posted quarterly Capital Expenditures of $4.9 million for Q4 2025, up 1233.88% year-over-year from $366000.0 in Q4 2024, and up 692.53% quarter-over-quarter from $616000.0 in Q2 2025.
Alumis (ALMS) Capital Expenditures (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Capital Expenditures for 3 consecutive years, with $4.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures rose 1233.88% year-over-year to $4.9 million; the TTM figure through Dec 2025 stood at $5.5 million (up 219.57% YoY), while the FY2025 annual figure was $5.5 million, up 219.57% from the prior year.
- Capital Expenditures rose to $4.9 million in Q4 2025 per ALMS's latest filing, from $616000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.9 million in Q4 2025 and bottomed at $37000.0 in Q1 2025.
- Historically, Capital Expenditures has averaged $1.2 million across 3 years, with a median of $616000.0 in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 1233.88% in 2025 and fell as far as 76.13% in 2025.
- Alumis' Capital Expenditures stood at $1.2 million in 2023, then tumbled by 69.75% to $366000.0 in 2024, then surged by 1233.88% to $4.9 million in 2025.
- Business Quant data shows ALMS's Capital Expenditures at $4.9 million in Q4 2025, $616000.0 in Q2 2025, and $37000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.88 Mn |
| Dec 31, 2025 | 4.88 Mn |
| Jun 30, 2025 | 616,000.00 |
| Jun 30, 2025 | 616,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Sep 30, 2024 | 779,000.00 |
| Sep 30, 2024 | 779,000.00 |
| Jun 30, 2024 | 432,000.00 |
| Jun 30, 2024 | 432,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Dec 31, 2023 | 1.21 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 2.17 Mn |
| Sep 30, 2023 | 2.17 Mn |